Murakami · Atherosclerosis 2002 · Controlled animal experiment · n=?

Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits.

Cited 72 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Non-human animal experimental study

PubMed 12048124 · doi:10.1016/s0021-9150(01)00764-x · record verified 2026-08-27

What was done

Watanabe heritable hyperlipidemic (WHHL) rabbits received taurine (0.3% in drinking tap water) for 24 weeks to evaluate its effects on atherosclerotic lesion progression, aortic lipid composition, acyl-CoA:cholesterol acyltransferase (ACAT) activity, macrophage infiltration, blood pressure, serum cholesterol, lipid peroxidation markers (TBARS), and ex vivo LDL oxidation resistance.

What was found

Taurine administration reduced aortic intimal lesion thickening by 31%. Cholesteryl ester content decreased by 35% in the aortic arch, 43% in the thoracic aorta, and 54% in the abdominal aorta, accompanied by reduced ACAT activity and fewer intimal macrophages. Serum and aortic TBARS fell by 29% and 50%, respectively, and isolated LDL showed greater resistance to copper-induced oxidation. Taurine had no measurable effect on blood pressure or circulating serum cholesterol levels.

Why it matters

This study demonstrates an anti-atherogenic mechanism for taurine driven by antioxidant activity, macrophage reduction, and inhibition of arterial cholesterol esterification, operating independently of circulating cholesterol reduction.

Limits

The study was performed exclusively in an animal model (WHHL rabbits) with an unspecified sample size (n not provided in the abstract), limiting direct clinical translation to humans. Long-term safety, optimal dosing regimens, and outcomes in non-genetic models of atherosclerosis were not established.

Cited by